Reisqs, J.-B.; Moreau, A.; Sleiman, Y.; Charrabi, A.; Delinière, A.; Bessière, F.; Gardey, K.; Richard, S.; Chevalier, P.
Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model. J. Pers. Med. 2023, 13, 335.
https://doi.org/10.3390/jpm13020335
AMA Style
Reisqs J-B, Moreau A, Sleiman Y, Charrabi A, Delinière A, Bessière F, Gardey K, Richard S, Chevalier P.
Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model. Journal of Personalized Medicine. 2023; 13(2):335.
https://doi.org/10.3390/jpm13020335
Chicago/Turabian Style
Reisqs, Jean-Baptiste, Adrien Moreau, Yvonne Sleiman, Azzouz Charrabi, Antoine Delinière, Francis Bessière, Kevin Gardey, Sylvain Richard, and Philippe Chevalier.
2023. "Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model" Journal of Personalized Medicine 13, no. 2: 335.
https://doi.org/10.3390/jpm13020335
APA Style
Reisqs, J.-B., Moreau, A., Sleiman, Y., Charrabi, A., Delinière, A., Bessière, F., Gardey, K., Richard, S., & Chevalier, P.
(2023). Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model. Journal of Personalized Medicine, 13(2), 335.
https://doi.org/10.3390/jpm13020335